CVD Clinical Trial
Official title:
Assessment of Brain-heart-muscle Axis Using EEG/MECG/EMG Combo Machine for Evaluating the Severity of Aortic Stenosis, Heart Failure and Ischemic Stroke Through an Artificial Intelligenceassisted System.
The specific objectives and methods of this project are: (1) To test the feasibility and accuracy of integrating EEG, MECG and EMG for detecting the severity of diseases such as aortic stenosis, heart failure and ischemic stroke. (2) Improve the accuracy of this multi-channel brain-heart-muscle device by using an artificial intelligence auxiliary system. (3) Provide tailor-made interdisciplinary treatment strategies for patients with different disease states.
Status | Not yet recruiting |
Enrollment | 750 |
Est. completion date | August 31, 2032 |
Est. primary completion date | July 31, 2032 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | 20 Years and older |
Eligibility | Inclusion criteria 1. Age=20 year-old 2. Healthy subjects or patients with A. Metabolic syndrome (MetS) ;B. HF with reduced ejection fractions (HFrEF, defined by left ventricular ejection fraction=40%) and current or previous symptoms of HF;C. Severe aortic stenosis (defined aortic valve area < 1.0 cm2 or mean pressure gradient = 40 mmHg), preparing to receive transcatheter aortic valve replacement ;D. Acute ischemic stroke and admitted to stroke intensive care unit (ICU), within 24 hours after onset The criteria of MetS includes: 1. Abdominal obesity: waist circumference (for Asians) = 90 cm in men and = 80 cm in women; 2. Hyperglycemia: serum fasting glucose level = 100 mg/dl, or receiving drug treatment for elevated blood sugar; 3. Reduced high-density lipoprotein cholesterol (HDL-C): serum HDL-C < 40 mg/dl in men and < 50 mg/dl in women or on cholesterol drug treatment; 4. Elevated triglycerides: serum triglyceride = 150 mg/dl or on drug treatment of hypertriglyceridemia; 5. Hypertension: systolic blood pressure = 130 mmHg, diastolic blood pressure = 85 mmHg, or on antihypertensive drug treatment. Exclusion criteria: 1. Under treatment for malignancy 2. Currently receiving immunosuppressants 3. Modified Rankin Scale (mRS) =2 prior to the stroke 4. Symptomatic HF in patients with acute ischemic stroke 5. Unable to perform neurocognitive function test 6. Unable to evaluate the physical activity using questionnaire or 6-minute walk test 7. Unable to cooperate with examinations using 3E combo machine. |
Country | Name | City | State |
---|---|---|---|
Taiwan | NTUH | Taipei |
Lead Sponsor | Collaborator |
---|---|
National Taiwan University Hospital |
Taiwan,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Composite cardiovascular outcome | Composite endpoint: Major adverse cardiac events (MACE): myocardial infarction, stroke, hospitalization for heart failure, or cardiovascular death) | up to 10 years |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT02480504 -
Effects of a 5:2 Diet on Weight Loss and Cardiovascular Risk Factors in Obesity
|
N/A | |
Completed |
NCT02440893 -
Understanding the Effect of Metformin on Corus CAD (or ASGES)
|
||
Completed |
NCT01486030 -
Effect of Exercise Stress Testing on Peripheral Gene Expression Using Corus CAD (or ASGES) Diagnostic Test
|
||
Active, not recruiting |
NCT00038727 -
Diabetes Prevention Program Outcomes Study
|
Phase 3 | |
Completed |
NCT03967678 -
Omega (n)-3 PUFA Enriched Beef & Health Outcomes.
|
N/A | |
Completed |
NCT01251302 -
Utility of a Molecular Personalized Coronary Gene Expression Test (Corus CAD or ASGES) on Cardiology Practice Pattern
|
||
Withdrawn |
NCT02158754 -
Clinician Utilization of Corus CAD (or ASGES) in Primary Care Provider Decision Making
|
||
Completed |
NCT01077388 -
e-Care for Heart Wellness
|
Phase 3 | |
Completed |
NCT04384029 -
The Geneva Covid-19 CVD Study
|
||
Active, not recruiting |
NCT02382822 -
Copenhagen Co-morbidity in HIV Infection Study
|
||
Active, not recruiting |
NCT01825668 -
Effect of Plant Sterol Enriched Milk on Plasma Lipid Levels of Humans Breast-fed During Infancy
|
N/A | |
Completed |
NCT02223286 -
Understanding Clinician Utilization of Corus CAD (Age/Sex/Gene Expression Score - ASGES) in Clinical Decision Making
|
N/A | |
Completed |
NCT00289237 -
Lifestyle Intervention in a General Population for Prevention of Ischaemic Heart Disease
|
N/A | |
Not yet recruiting |
NCT03658031 -
Effect of Dapagliflozin on the Progression From Prediabetes to T2DM in Subjects With Myocardial Infarction
|
Phase 3 | |
Completed |
NCT03636529 -
Tart Cherry Juice and Markers of Inflammation, CVD, and Diabetes
|
N/A | |
Completed |
NCT00500617 -
Personalized Risk Evaluation and Diagnosis (Using Corus CAD or ASGES) in the Coronary Tree
|
||
Completed |
NCT00500708 -
Diagnostic Investigation of Sudden Cardiac Event Risk
|
N/A | |
Completed |
NCT01255852 -
Atorvastatin for Preventing Occlusion and Restenosis After Intracranial Artery Stenting
|
Phase 4 | |
Completed |
NCT00583297 -
Genetic Substudy of the Alternans Before Cardioverter Defibrillator (ABCD) Trial
|
N/A | |
Completed |
NCT02405754 -
Clinical Utility of an Age, Sex, and Gene Expression Score (ASGES or Corus CAD) in African American Patients.
|